New Delhi, April 4 -- India is unlikely to face a significant impact fr0m the United States' decision to impose steep tariffs on certain patented drugs, according to the Global Trade Research Initiative (GTRI).

The move follows an executive order signed by US President Donald Trump on April 2, introducing a 100 per cent ad valorem duty on imports of select patented pharmaceuticals and related ingredients.

GTRI noted that India remains largely protected, as its pharmaceutical exports to the US are dominated by low-cost generic medicines rather than patented drugs, PTI reported.

Generics Exempt, For Now

Generic medicines, which account for over 90 per cent of drug consumption in the US, have been exempted fr0m the new tariffs. This exem...